The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer

T Kajita 1, Y Ohta 1, K Kimura 1, M Tamura 1, Y Tanaka 1, Y Tsunezuka 1, M Oda 1, T Sasaki 2 and Go Watanabe 1

1First Department of Surgery, Kanazawa University School of Medicine, Takara-machi 13-1, Kanazawa 920-8641, Japan; 2Department of Experimental Therapeutics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Summary Expression of vascular endothelial growth factor (VEGF)-C and that of its receptors were assessed in non-small cell lung cancer. Immunohistochemistry revealed positive VEGF-C expression in 38.7% (24/62) of the patients studied. A significant positive correlation was found between VEGF-C in cancer cells and VEGF receptor-2 (VEGFR-3) and VEGF receptor-3 (VEGFR-3) in vascular endothelial cells, but not between VEGF-C in cancer cells and VEGFR-2 in endothelial cells. In this cohort of lung cancer patients, VEGF-C expression was significantly associated with lymph node metastasis, lymphatic vessel invasion, and worse outcomes after the operation. Although the independent prognostic impact of VEGF-C and VEGFR-3 was not clear, VEGFR-2 expression in endothelial cells retained the independency as the prognostic indicator. In light of these findings, we conclude that VEGF-C plays an important role in lymphatic invasion/metastasis and tumour progression in non-small cell lung cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: VEGF-C; lung cancer; lymph node metastasis; VEGFR

Tumour progression is regulated by a number of stimulators and inhibitors of tumour angiogenesis (Folkman, 1995). Among the angiogenesis stimulators, vascular endothelial growth factor (VEGF) has been shown to be the most powerful mitogen for endothelial cells. Among VEGF members, VEGF-C has recently been found to induce not only angiogenesis but also lymphangiogenesis via VEGF receptor-2 (VEGFR-2) and VEGF receptor-3 (VEGFR-3) (Mustonen et al, 1995; Cao et al, 1998; Yonekura et al, 1999). A few researchers have reported the possible association of VEGF-C expression with intratumoural lymphatic vessel density or lymph node metastasis in some neoplasms (Ohta et al, 1999; Tsurusaki et al, 1999; Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000). Of importance, some studies have recently shown that VEGF-C-mediated tumour lymphangiogenesis promotes cancer metastasis including nodal metastasis (Mandriota et al, 2001; Skobe et al, 2001). In the present study, we assessed the expression of VEGF-C and its receptors to better delineate their association with lymph node metastasis and cancer progression in non-small cell lung cancer.

MATERIALS AND METHODS

Immunohistochemistry for VEGF-C and VEGFRs

The primary antibodies used in this study were an anti-VEGF-C goat polyclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGF-C rabbit polyclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGF-C rabbit monoclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), and an anti-CD34 mouse monoclonal antibody (Nichirei, Tokyo, Japan). Paraffin sections were deparaffinized and immunohistochemical staining was performed using the immunoperoxidase technique. Endogenous peroxidase was blocked by treatment with 0.3% hydrogen peroxide in methanol for 15 min, and the sections were washed with Dulbecco’s phosphate-buffered saline (pH 7.2) without calcium ion or magnesium ion (PBS–). Tissue non-specific binding sites were blocked by 10% normal rabbit serum for VEGF-C, and by 10% normal goat serum for VEGF-2, VEGFR-3 and CD34 for 15 min at room temperature. After they had been washed with PBS–, the sections were reacted with antibodies for 16 h at 4°C. Then they were washed with PBS– and reacted with biotinylated secondary antibody for 30 min at room temperature. After they had been washed with PBS–, avidin-biotin-peroxidase complex (DAKO LSAB2 system, DAKO Co, Carpinteria, CA, USA) was added and colour was developed using 3-3’-diaminobenzidine (Sigma, St Louis, MO, USA) with 0.03% hydrogen peroxide. Counterstaining was done with haematoxylin. For the negative control, all reagents except for the primary antibody were used. The specificities of VEGF-C and VEGFR-3 were...
tested using a blocking peptide (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA).

**Assessment of microvessel density and immunohistochemical assessment of VEGF-C, VEGFR-2, and VEGFR-3**

The total number of vascular endothelial cells was determined by immunohistochemistry for CD34 (Figure 1). The number was assessed blindly by 2 investigators. After the areas of highest vascularization had been chosen under low power (100× magnification), vessel count within tumours was carried out in 3 fields on the screen image which was captured at 200× magnification. The average counts of the 3 fields were recorded, and the mean value of the 2 investigators was used for the total number. For evaluation of immunostainings, cases in which at least 5% of tumour cells were immunoreactive were defined as being positive. As for the VEGFR-2 and VEGFR-3 staining within tumour cells, cases in which more than 50% of tumour cells were immunoreactive were defined as being strongly positive. As for the VEGFR-2 and VEGFR-3 staining within endothelial cells, after counting the total number of endothelial cells by CD34 staining as described above, the number of VEGFR-2- or VEGFR-3-positive endothelial cells was determined in the same manner by using consecutive paraffin sections. Cases in which at least 5% of endothelial cells were immunoreactive were defined as being positive in this study.

**Western blot analysis of VEGFR-3 in human lung cancer cell lines**

5 human lung cancer cell lines (PC-3, PC-8, PC-10, PC-14, QG-56) were used and maintained in RPMI-1640 media (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES buffer, 500 units ml⁻¹ pencillin and 500 units ml⁻¹ streptomycin at 37°C and 5% CO₂. HUVEC was used as a positive control for VEGFR-3 and maintained in medium 199 (Life Technologies, Grand Island, NY, USA) supplemented with 20% FBS, 100 μg ml⁻¹ EC growth supplement, 50 U ml⁻¹ heparin, glutamine and antibiotics. 20 μg of protein sample were obtained from each cell line and mixed with 6 μl of sample buffer (50 mM Tris-HCl (pH 6.5), 10% glycerol, 2% SDS, and 0.1% bromphenol blue) prior to separation by 10% sodium dodecyl sulfate-polyacrylamide gel, followed by electrophotetic transfer of the proteins to a PVDF membrane (Millipore, Bedford, MA). The transferred samples were reacted with an anti-VEGFR-3 polyclonal antibody at 1:1000 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) and anti-β-actin monoclonal antibody (Sigma Chemical Co, St Louis, MO) for 2 h at room temperature. Secondary antibody, anti-mouse coupled to horseradish peroxidase, was incubated with the membrane and then washed in TBS-T. The presence of secondary antibody bound to membrane was detected by using the ECL Western blotting detection reagent (Amersham Life Science, Buckinghamshire, UK). As a negative control, primary VEGFR-3 antibody, which was pre-absorbed with the blocking peptide (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) overnight was used.

**Statistics**

Fisher’s exact test was used to examine the association between different variables and clinicopathological factors. Survival curves were obtained using the Kaplan–Meier method and compared using the log-rank test. A multivariate model using the Cox stepwise regression analysis was used to evaluate the statistical strength of independent association between selected covariates and patient survival. A P value less than 0.05 was considered significant.

**RESULTS**

**VEGF-C, VEGFR-2 and VEGFR-3 expression in lung cancer tissue**

VEGF-C antigen was observed in the cytoplasm of cancer cells (Figure 2). No staining was observed in the normal lung tissue. VEGF-C expression was positive in 38.7% (24/62) of the lung cancer patients. VEGFR-2 and VEGFR-3 antigens were observed in the cytoplasm of endothelial cells and cancer cells (Figure 3). The percentages of patients with positive VEGFRs in endothelial cells were 64.5% (40/62) for VEGFR-3 and 74.1% (46/62) for VEGFR-2. The percentages of patients with positive VEGFRs in cancer cells were 77.4% (48/62) for VEGFR-3 and 100% (62/62) for VEGFR-2. The percentages of the patients with strongly positive VEGFR staining in cancer cells were 27.4% (17/62) for VEGFR-3 and 51.6% (32/62) for VEGFR-2. A significant positive correlation was found between VEGF-C expression in cancer cells
and VEGFR-3 expression in endothelial cells \((P < 0.01)\), but not between VEGF-C in cancer cells and VEGFR-2 in endothelial cells (Table 1). Moreover, the expression of VEGF-C in cancer cells was also significantly associated with the intensities of both VEGFR-2 and VEGFR-3 staining in cancer cells (both \(P < 0.05\)) (Tables 1, 2). As a result of the Western blot analysis, a Mr 125 000 band corresponding to VEGFR-3 protein was detected in all 5 lung cancer cell lines used (Figure 4).

**Correlations between VEGF-C expression and clinicopathological factors**

Table 3 shows the correlations between clinicopathological factors and VEGF-C expression. VEGF-C expression was more frequently found in tumours with lymph node metastasis than in those without it \((P < 0.05)\). VEGF-C expression in tumours with lymphatic invasion was significantly greater than that in tumours

**Table 1** Correlation between VEGF-C and VEGFR-3 expression

| Expression of VEGF-C | No. of cases | No. (%) of cases with strong positive VEGFR-3 (T) | \(P\) value | No. (%) of cases with positive VEGFR-3 (EC) | \(P\) value |
|----------------------|-------------|-------------------------------------------------|-------------|------------------------------------------|-------------|
| Positive             | 24          | 10 (41.6%)                                      | 0.045       | 21 (87.5%)                               | 0.003       |
| Negative             | 38          | 7 (18.4%)                                       |             | 19 (50.0%)                               |             |

VEGF-3 (T), VEGFR-3 expression in tumour cells; VEGFR-3 (EC), VEGFR-3 expression in endothelial cells.

**Table 2** Correlation between VEGF-C and VEGFR-2 expression

| Expression of VEGF-C | No. of cases | No. (%) of cases with strong positive VEGFR-2 (T) | \(P\) value | No. (%) of cases with positive VEGFR-2 (EC) | \(P\) value |
|----------------------|-------------|-------------------------------------------------|-------------|------------------------------------------|-------------|
| Positive             | 24          | 17 (70.8%)                                      | 0.016       | 19 (79.1%)                               | 0.476       |
| Negative             | 38          | 15 (39.4%)                                      |             | 27 (71.0%)                               |             |

VEGF-2 (T), VEGFR-2 expression in tumour cells; VEGFR-2 (EC), VEGFR-2 expression in endothelial cells.
without lymphatic invasion \((P < 0.05)\). The VEGF-C expression was also significantly associated with gender and pathological stage (both \(P < 0.05\)) (Table 3).

**Correlations of clinicopathological and biological factors with survival**

Figure 5 shows the survival of patients according to the VEGF-C status. Patients with VEGF-C expression had significantly poorer outcomes compared to those without \((P < 0.05)\). From multivariate analysis, VEGFR-2 expression in endothelial cells, T factor and N factor retained independent negative prognostic impact on overall survival (Table 4).

**DISCUSSION**

The findings of the current study demonstrated the positive association of VEGF-C expression with both lymph node metastasis and lymphatic invasion in lung cancer. In addition, a significant positive correlation was clearly found between VEGF-C expression in cancer cells and VEGFR-3 expression in endothelial cells. A positive association of VEGF-C expression with lymph node metastasis has been reported in gastric cancer, prostatic cancer, lung adenocarcinoma, and colorectal cancer (Tsurusaki et al, 1999; Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000). A significant correlation between VEGF-C and VEGFR-3 has also been found in malignant mesothelioma and gastric cancer (Ohta et al, 1999; Yonemura et al, 1999). Our results indicated the possibility that VEGF-C produced in lung cancer cells modulates lymphatic metastasis through its receptor, VEGFR-3, in endothelial cells.

To our knowledge, this is the first report that described the prognostic aspect of VEGF-C expression in lung cancer. The lung cancer patients with VEGF-C expression had significantly poorer outcomes compared to those without it. Although we could find no prognostic independency in VEGF-C and VEGFR-3, the VEGFR-2 expression in endothelial cells retained significance.

| Table 3 | Correlation between VEGF-C expression and clinicopathological factors |
|---------|---------------------------------------------------------------|
| Factors | No. of cases | Case no. (%) of VEGF-C positive | \(P\) value |
| Sex     |              |                                 |            |
| Male    | 45           | 21 (46.6)                        | 0.036      |
| Female  | 17           | 3 (17.6)                         |            |
| Age     |              |                                 |            |
| \(\leq 65\) | 24 | 8 (33.3)                        | 0.489      |
| \(> 65\)  | 38           | 16 (42.1)                        |            |
| Histology |            |                                 |            |
| Adenocarcinoma | 36 | 9 (25.0)                        | 0.320      |
| Squamous cell carcinoma | 30 | 12 (60.0)                   |            |
| Adenosquamous cell carcinoma | 2 | 2 (100.0)                   |            |
| Large cell carcinoma | 4  | 1 (25.0)                       |            |
| Histopathological grading |              |                                 |            |
| Well differentiated | 21 | 6 (28.5)                        | 0.059      |
| Moderately differentiated | 21 | 8 (38.0)                        |            |
| Poorly differentiated | 15 | 8 (53.3)                        |            |
| T factor |              |                                 |            |
| T1      | 22           | 7 (31.8)                         | 0.117      |
| T2, 3, 4 | 40           | 21 (52.5)                        |            |
| N factor |              |                                 |            |
| Positive | 25           | 14 (56.0)                        | 0.021      |
| Negative | 37           | 10 (27.0)                        |            |
| Ly invasion |          |                                 |            |
| Positive | 24           | 14 (58.3)                        | 0.011      |
| Negative | 38           | 10 (26.3)                        |            |
| v invasion |          |                                 |            |
| Positive | 20           | 9 (45.0)                         | 0.480      |
| Negative | 42           | 15 (35.7)                        |            |
| Stage   |              |                                 |            |
| I, II   | 25           | 9 (36.0)                         | 0.718      |
| III, IV | 37           | 15 (40.5)                        |            |
Results of Cox hazard model analysis of prognostic factors
Kaplan–Meier survival plots for lung cancers subdivided according to the VEGF-C expression. The difference in survival between the positive group (closed circle) and negative group (open circle) was significant (* P < 0.05)

Table 4 Results of Cox hazard model analysis of prognostic factors (multivariate)

| Parameters | χ²  | p value | 95% CI   |
|------------|-----|---------|----------|
| VEGF-C positive | 2.73 | 0.099 | 0.86–5.83 |
| VEGF-R (EC) positive | 8.54 | 0.004 | 1.0–6.41 |
| T1 vs. T2–4 | 6.82 | 0.009 | 1.71–42.06 |
| N0 vs. N1–3 | 9.07 | 0.003 | 3.33–54.60 |
| Stage I, II vs. III, IV | 2.58 | 0.108 | 0.05–1.34 |

VEGFR-2, which is a receptor for VEGF, VEGF-C, VEGF-D and VEGF-E, is known to also act as the main regulator of endothelial cell proliferation and migration (Wallenberger et al, 1994; Joukov et al, 1996; Ferrara and Davis-Smyth, 1997; Achen et al, 1998; Meyer et al, 1999). We speculate that VEGF-R plays a key role in tumour angiogenesis and tumour progression/development in lung cancer. It is notable that our immunohistochemical study showed positive VEGF-R stainings not only in endothelial cells but also in cancer cells. Both VEGF-R-1 and VEGF-R-2 expressions have been observed in breast cancer, ovarian cancer, prostate cancer and melanoma in addition to lung cancer (Gitay-Goren et al, 1993; Boocock et al, 1995; Lu and Brodie, 1996; Decaussin et al, 1999; Ferrer et al, 1999; Speirs and Atkin, 1999; Xie et al, 1999). On the other hand, although the existence of VEGF-R-3 expression in cancer cells has been reported in malignant mesothelioma, Kaposi’s sarcoma, vascular tumour and melanoma (Pajusola et al, 1992; Jussila et al, 1998; Lymphousaki et al, 1998; Ohta et al, 1999), there has been no report on VEGF-R-3 expression within lung cancer cells. Our results demonstrated here seem to strengthen the notion that lung cancer cells express VEGF-R-3. Considering the positive association found between VEGF-C expression in lung cancer cells and VEGF-R-2/VEGF-R-3 stainings in cancer cells, the role of VEGF-C may encompass the tumour growth regulation in both paracrine and autocrine fashion. Although the prognostic impact of VEGF-Rs expression within cancer cells was not clear in this study, examination of the activation status through tyrosin phosphokinase is required to further elucidate the roles of VEGF-Rs in lung cancer cells.

In conclusion, this study enlightens the evidence that VEGF-C expression within cancer cells and VEGF-R-3 expression within endothelial cells are of influence on the lymphatic metastasis in non-small cell lung cancer. Further analysis concerning lymphangiogenesis within tumour should be a promising way to understand the mechanism underlying the lymphatic metastasis in non-small cell lung cancer.

REFERENCES

Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk-1) and VEGF receptor 3 (Flt-3). Proc Natl Acad Sci USA 95: 548–553
Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y and Sugimachi K (2000) Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 83: 887–891
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentymann PR and Smith SK (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Nat Cancer Inst 87: 506–516
Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson WL and Alitalo K (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 95: 14389–14394
Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C and Brambilla E (1997) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flk-1 and VEGF-R2 Flk/KDR) in non-small cell lung carcinomas (NSCLCs). J Pathol 188: 367–377
Ferrara N and Davis-Smyth (1997) The biology of vascular endothelial growth factor. Endocrine Rev 18: 4–25
Ferrer FA, Miller LJ, Lindquist R, Kowalczycz P, Laudeine VP, Albertsen PC and Kreutzer DL (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567–572
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27–31
Gitay-Goren H, Halaban R and Neufeld G (1993) Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190: 702–708
Joukov V, Pajusela K, Kaipainen A, Chilov D, Lahinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K (1996) A novel vascular endothelial growth factor. VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290–298
Jussila L, Vallota R, Partanen TA, Salven P, Heikkila P, Mattikainen M-T, Renkonen R, Kaipainen A, Dietmar M, Tischacher E, Alitalo R and Alitalo K (1998) Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 58: 1599–1604
Lu Q and Brodie A (1996) Stimulation of the growth of MCF-7 and MDA-MB-468 breast cancer cells by vascular endothelial growth factor. Proc Am Assoc Cancer Res 37: 1499
Jussila L, Partanen TA, Olofsson B, Thomas-Crussells J, Fletcher C, deWaal R, Kaipainen A and Alitalo K (1998) Expression of the vascular endothelial growth factor receptor-3 in lymphatic endothelium of the skin and in vascular tumours. Am J Pathol 153: 395–403
Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G and Alitalo K (1998) Vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. Br J Cancer 81: 54–61

© 2001 Cancer Research Campaign British Journal of Cancer (2001) 85(2), 255–260

VEGF-C expression in lung cancer 259
Pajusola K, Aprelikova O, Korhonen I, Kaipainen A, Pertovaara L, Alitalo R and Alitalo K (1992) FLT-4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 52: 5738–5743

Skobe M, Hawighorst T, Jackson D, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature med 7: 192–198

Speirs V and Atkin SL (1999) Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 80: 898–903

Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K and Koji T (1999) Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 80: 309–313

Waltenberger J, Claesson-Welsh L, Sieghahn A, Shibuya M and Heldin CH (1994) Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988–26995

Xie B, Tam NNC, Tsao SW and Wong YC (1999) Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone induced mammary cancer in the Noble rat. Br J Cancer 81: 1335–1343

Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin MJ, Uneki H, Yamamoto Y and Yamamoto H (1999) Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 274: 35172–35178

Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K and Sasaki T (1999) Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5: 1823–1829